Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab.

Schwarz CW, Rasmussen MK, Bertelsen T, Iversen L, Skov L, Loft N

Open source

DOI
10.1001/jamadermatol.2025.3928
Published
2025 Dec 1
Container
JAMA dermatology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1001/jamadermatol.2025.3928,
  title = {Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab.},
  author = {Schwarz CW and Rasmussen MK and Bertelsen T and Iversen L and Skov L and Loft N},
  year = {2025},
  journal = {JAMA dermatology},
  doi = {10.1001/jamadermatol.2025.3928},
  url = {https://doi.org/10.1001/jamadermatol.2025.3928}
}

RIS

TY  - JOUR
TI  - Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab.
AU  - Schwarz CW
AU  - Rasmussen MK
AU  - Bertelsen T
AU  - Iversen L
AU  - Skov L
AU  - Loft N
PY  - 2025
JO  - JAMA dermatology
DO  - 10.1001/jamadermatol.2025.3928
UR  - https://doi.org/10.1001/jamadermatol.2025.3928
ER  - 

APA

CW, S., MK, R., T, B., L, I., L, S., & N, L. (2025). Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab.. JAMA dermatology. https://doi.org/10.1001/jamadermatol.2025.3928

Source records